Gram-Negative Bacterial Infections Global Clinical Trials Review, H2, 2017

2017-08-30
Price :
Published : Aug-2017
No. of Pages : 1110
order by fax Inquire before Buying request discount
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Gram-Negative Bacterial Infections Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Gram-Negative Bacterial Infections 31
Jun 30, 2017: Entasis Publishes Data Highlighting the Potent and Differentiated Activity of ETX2514 Combinations against Drug Resistant Gram-negative Bacteria Including Acinetobacter and Pseudomonas 31
Jun 05, 2017: Zavante Therapeutics Reports ZOLYD Broad Spectrum Activity and Synergy With Multiple Antibiotics; in vitro Studies Presented at ASM Microbe 2017 Meeting 31
Jun 01, 2017: Achaogen Initiates C-Scape Clinical Development Program with Phase 1 Study of Orally-Administered Antibacterial Candidate 32
Jun 01, 2017: Matinas BioPharma to Provide Update on its Antibiotic Product Candidate, MAT2501, at the 2017 Jefferies Global Healthcare Conference 32
May 31, 2017: Allergan to Present Data on AVYCAZ at ASM Microbe 2017 in New Orleans 32
May 31, 2017: Allergan to Present Data on ATM-AVI at ASM Microbe 2017 in New Orleans 33
Clinical Trial Profile Snapshots 34
Appendix 1108
Abbreviations 1108
Definitions 1108
Research Methodology 1109
Secondary Research 1109
About GlobalData 1110
Contact Us 1110
Source 1110

List of Tables
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Region, 2017* 7
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 16
Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 19
Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Phase, 2017* 22
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Gram-Negative Bacterial Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30

List of Figures
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 16
Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 19
Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Gram-Negative Bacterial Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
GlobalData Methodology 1109
Filed in: Pharmaceutical
Publisher : GlobalData